Catalog No.: PC-49323Not For Human Use, Lab Use Only.
KNX-115 (KNX115) is a potent, selective inhibitor of plasmodium falciparum myosin A (PfMyoA), inhibits PfMyoA actin-activated ATPase with Ki of 17 nM, >50-fold selectivity against cardiac, skeletal, and smooth muscle myosins.
KNX-115 (KNX115) is a potent, selective inhibitor of plasmodium falciparum myosin A (PfMyoA), inhibits PfMyoA actin-activated ATPase with Ki of 17 nM, >50-fold selectivity against cardiac, skeletal, and smooth muscle myosins.
KNX-115 inhibits the blood and liver stages of Plasmodium with an EC50 of 110 nM, with negligible liver cell toxicity.
KNX-115 inhibits sporozoite cell traversal and blocks the gametocyte to oocyst conversion in the mosquito.
NX-115 displays a similar killing profile to pyrimethamine and parasites are totally killed after 96 hours of treatment.
KNX-115 is equally effective at inhibiting a panel of Plasmodium strains resistant to experimental and marketed antimalarials.
